PreveCeutical Medical Inc. announced that it has completed a systematic and comprehensive series of in silico guided design, synthesis and potency screening of a library of carefully designed peptide constructs intended for development as non-addictive analgesics. Through this meticulous process the company has identified no less than five novel peptide constructs, which preferentially target the receptor subtype which is of interest to the Company and is purported to avoid addictive and tolerance-inducing side effects.